UY33562A - Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma - Google Patents

Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma

Info

Publication number
UY33562A
UY33562A UY0001033562A UY33562A UY33562A UY 33562 A UY33562 A UY 33562A UY 0001033562 A UY0001033562 A UY 0001033562A UY 33562 A UY33562 A UY 33562A UY 33562 A UY33562 A UY 33562A
Authority
UY
Uruguay
Prior art keywords
bradicinine
glaucoma
treatment
receptors agonists
eye hypertension
Prior art date
Application number
UY0001033562A
Other languages
English (en)
Inventor
Chen Hwang-Hsing
Combrink Keith
Hellberg Mark
Mohapatra Suchismita
Namil Abdelmoula
Pang Iok-Hou
Prassana Ganesh
Severns Bryon
Sharif Najam
Original Assignee
Alcon Res Ltd
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd, Astellas Pharma Inc filed Critical Alcon Res Ltd
Publication of UY33562A publication Critical patent/UY33562A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención da a conocer composiciones y métodos para tratar y/o prevenir trastornos oculares asociados con la presión intraocular elevada. En particular, los compuestos son agonistas de la bradicinina.
UY0001033562A 2010-08-18 2011-08-17 Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma UY33562A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37474010P 2010-08-18 2010-08-18

Publications (1)

Publication Number Publication Date
UY33562A true UY33562A (es) 2011-10-31

Family

ID=44720101

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033562A UY33562A (es) 2010-08-18 2011-08-17 Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma

Country Status (5)

Country Link
US (2) US8252793B2 (es)
AR (1) AR082706A1 (es)
TW (1) TW201210584A (es)
UY (1) UY33562A (es)
WO (1) WO2012024419A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103622961B (zh) * 2013-09-06 2016-03-02 武汉光谷百桥国际生物科技有限公司 一种非肽类缓激肽b2受体激动剂在促进毛发生长方面的应用
BR112018014525A2 (pt) * 2016-01-14 2018-12-11 Handok Inc compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos
EP3615053A4 (en) 2017-04-25 2021-07-14 Temple Otorongo LLC PHARMACEUTICAL COMPOSITION CONSISTING OF TRYPTOPHAN AND A PHYLLOKININ DERIVATIVE FOR USE IN THE TREATMENT OF PSYCHIATRIC AND PSYCHOLOGICAL DISORDERS

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212196A (en) 1986-10-21 1993-05-18 Alcon Laboratories, Inc. Control of post-surgical intraocular pressure using clonidine derivatives
US5500230A (en) 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US4883814A (en) 1987-05-18 1989-11-28 Merck & Co., Inc. 1-aryloxy-3-(substituted alkylamino)-2-propanols and use as β-blocker
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5538966A (en) 1994-01-21 1996-07-23 Alcon Laboratories, Inc. Carbonic anhydrase inhibitors
US5464831A (en) 1994-09-09 1995-11-07 Alcon Laboratories, Inc. Thienothiadiazine sulfonamides useful as carbonic anhydrase inhibitors
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5620970A (en) 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5612364A (en) 1995-11-08 1997-03-18 Alcon Laboratories, Inc. Substantially pure apraclonidine
GB9602029D0 (en) * 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
US6156753A (en) 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2310230C (en) 1997-12-23 2008-05-06 Alcon Laboratories, Inc. The use of brinzolamide to prevent visual field loss
DE19809436A1 (de) 1998-03-05 1999-09-09 Braun Gmbh Aufsatz für ein Gerät zum Auszupfen von Haaren der menschlichen Haut
WO1999051235A1 (en) 1998-04-03 1999-10-14 Alcon Laboratories, Inc. Non-peptide bradykinin receptor antagonists for use in controlling intraocular pressure and treating glaucoma
FR2777189B1 (fr) 1998-04-09 2001-04-06 Chauvin Lab Sa Composition ophtalmique comprenant un beta-bloquant
JP2002526443A (ja) 1998-09-18 2002-08-20 アルコン ラボラトリーズ， インコーポレーテッド 緑内障治療用セロトニン作動性５ｈｔ２作用物質
WO2004073708A1 (en) 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US6358949B1 (en) 1999-04-02 2002-03-19 Neurogen Corporation Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors
US7005446B1 (en) 1999-04-20 2006-02-28 Alcon Manufacturing, Ltd. Use of AP-1 activators to treat glaucoma and ocular hypertension
EP1200133A4 (en) 1999-07-12 2003-05-28 Walter Gehring HANDLING OF FABRIC OR ORGAN TYPE USING THE NOTCH WAY
HU225917B1 (en) 1999-09-16 2007-12-28 Tanabe Seiyaku Co Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use
JP4779255B2 (ja) 2001-07-16 2011-09-28 パナソニック株式会社 レーザ光源
EP2221054A1 (en) 2002-04-30 2010-08-25 Alcon, Inc. CDK inhibitors for lowering intraocular pressure
US20050244461A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
WO2006041875A1 (en) 2004-10-06 2006-04-20 Allergan, Inc. Novel prostamides for the treatment of glaucoma and related diseases
US8092838B2 (en) 2005-04-29 2012-01-10 The University Of Houston System Use of hydrogen sulfide in the treatment of eye diseases

Also Published As

Publication number Publication date
US8252793B2 (en) 2012-08-28
US20120283260A1 (en) 2012-11-08
TW201210584A (en) 2012-03-16
US20120046285A1 (en) 2012-02-23
WO2012024419A2 (en) 2012-02-23
WO2012024419A3 (en) 2012-04-05
AR082706A1 (es) 2012-12-26

Similar Documents

Publication Publication Date Title
PH12018500658A1 (en) Methods of treating intraocular pressure with activators of tie-2
MY171920A (en) Prevention and treatment of ocular conditions
AR091237A1 (es) Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
PH12017500922A1 (en) Stabilized omega-3 ophthalmic compositions
WO2014143754A3 (en) Prostamide-containing intraocular implant
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
UY38926A (es) INHIBICIÓN DE INTEGRINA alfa4beta7 HUMANA
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
CL2012002612A1 (es) Compuestos derivados de benciloxicicloalquiladenosina, como agonistas selectivos de receptores de adenosina a1; composicion farmaceutica oftalmica; y su uso para el tratamiento de una afeccion seleccionada entre presion intraocular elevada, hipertension ocular o glaucoma.
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
UY32214A (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
UY33153A (es) Formulación tópica oftálmica de péptidos
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
CR20130094A (es) Agonistas de adenosina a1 para el tratamiento del glaucoma y la hipertensión ocular
IT1398378B1 (it) Citicolina per il trattamento del glaucoma e dell'ipertensione oculare.
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
IL274378A (en) Conjugate of phosphorylcholine and toftsin for the treatment of ocular inflammatory diseases
ITMI20070890A1 (it) Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
UY33562A (es) Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2017007578A (es) Farmacoterapia para prevenir o tratar glaucoma.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20210707